Table 4.
Bleeding Score in the Treatment Groups.a
Bleeding Score | Total | |||
---|---|---|---|---|
0 | 1 | 2 | ||
Imatinib | 35 (74.5%), (11b) | 10 (21.3%), (0b) | 2 (4.3%), (1b) | 47 (100%), (12b) |
Dasatinib | 12 (80%), (4b) | 2 (13.3%), (1b) | 1 (6.7%), (0b) | 15 (100%), (5b) |
Nilotinib | 6 (100%), (1b) | 0, (0b) | 0, (0b) | 6 (100%), (1b) |
aThere was no significant difference (P = .65).
bThe patients with a secretion defect on platelet aggregometry.